Skip to main content

View full-text article in PMC

. 2019 Jan 15;14(1):e0210443. doi: 10.1371/journal.pone.0210443

Table 7. Median blood CNI (tacrolimus and cyclosporine A) levels during long-term follow-up.

	Induction therapy			p-value
	No	ATG	Alemtuzumab	p-value
3 months	12.7 (2.10–120.40)	12.80 (2–86)	10.30 (2–81)	^*<0.001, ^<0.001**
6 months	10.8 (2–46.7)	11.7 (2–55.6)	9.3 (2.4–55)	^*<0.001, ^<0.001**
1 year	9.1 (2–54.1)	10.1 (2.7–59.1)	7.8 (2.1–48)	^*<0.001, ^**<0.001
2 years	6.4 (2–39.6)	7.1 (2.1–22.6)	6.4 (2–34.3)	^*<0.001, ^**<0.001
3 years	6.3 (2–41.3)	5.1 (2.1–59)	6.6 (2.1–29.7)	^0.107, ^*<0.001
≥ 4 years	6.2 (2.1–22.4)	4.3 (2–15.9)	5.9 (2–22.1)	^0.087, <0.001*
	Induction therapy			p-value
	No	ATG	Ca	p-value
3 months	270 (34–3298)	242 (61–738)	158 (34–1380)	^*<0.001, ^**<0.001
6 months	213 (37–1243)	256 (31–454)	191.5 (153–343)	^0.219, ^*<0.001
1 year	190 (60–1984)	130 (67–486)	192 (114–257)	^0.078, ^*<0.001
2 years	164 (30–836)	135 (40–337)	152 (120–303)	^0.040, ^*<0.001
3 years	112 (31–658)	75.5 (39–289)	94 (30–443)	^0.058, ^*<0.05
≥ 4 years	98 (30–494)	69 (30–686)	93 (44–168)	^0.087, ^*<0.05

* NI vs Alemtuzumab;

** ATG vs Alemtuzumab